MA26832A1 - Derives de benzodiazepine. - Google Patents

Derives de benzodiazepine.

Info

Publication number: MA26832A1
Authority: MA; Morocco
Prior art keywords: benzodiazepine derivatives; benzodiazepine; derivatives
Prior art date: 1999-10-15

Application number

MA26602A

Other languages

English (en)

Inventor

Alexander Alanine

Vincent Mutel

Thomas Johannes Woltering

Geo Adam

Erwin Goetschi

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-15

Filing date

2002-04-15

Publication date

2004-12-20

2002-04-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26832A1 publication Critical patent/MA26832A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)

MA26602A 1999-10-15 2002-04-15 Derives de benzodiazepine. MA26832A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99120519		1999-10-15

Publications (1)

Publication Number	Publication Date
MA26832A1 true MA26832A1 (fr)	2004-12-20

Family

ID=8239206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26602A MA26832A1 (fr)	1999-10-15	2002-04-15	Derives de benzodiazepine.

Country Status (35)

Country	Link
US (4)	US6509328B1 (fr)
EP (1)	EP1224175B1 (fr)
JP (1)	JP3886805B2 (fr)
KR (1)	KR100481386B1 (fr)
CN (1)	CN1199954C (fr)
AR (1)	AR026028A1 (fr)
AT (1)	ATE261945T1 (fr)
AU (1)	AU779874B2 (fr)
BR (1)	BR0014761A (fr)
CA (1)	CA2386980C (fr)
CO (1)	CO5251454A1 (fr)
CZ (1)	CZ20021663A3 (fr)
DE (1)	DE60009116T2 (fr)
DK (1)	DK1224175T3 (fr)
ES (1)	ES2215738T3 (fr)
GC (1)	GC0000207A (fr)
HR (1)	HRP20020260B1 (fr)
HU (1)	HUP0203294A3 (fr)
IL (2)	IL149104A0 (fr)
JO (1)	JO2299B1 (fr)
MA (1)	MA26832A1 (fr)
MX (1)	MXPA02003740A (fr)
MY (1)	MY125506A (fr)
NO (1)	NO20021691D0 (fr)
NZ (1)	NZ518037A (fr)
PE (1)	PE20010759A1 (fr)
PL (1)	PL357433A1 (fr)
PT (1)	PT1224175E (fr)
RU (1)	RU2257382C2 (fr)
SI (1)	SI1224175T1 (fr)
TR (1)	TR200201026T2 (fr)
TW (1)	TWI254044B (fr)
WO (1)	WO2001029012A2 (fr)
YU (1)	YU27902A (fr)
ZA (1)	ZA200202654B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ518037A (en)	1999-10-15	2004-04-30	F	Benzodiazepine derivatives useful as metabotropic glutamate receptors
KR100566178B1 (ko) *	2001-04-12	2006-03-29	에프. 호프만-라 로슈 아게	ｍＧｌｕＲ2 길항물질 Ｉ로서의디하이드로-벤조[ｂ][1,4]디아제핀-2-온 유도체
HRP20030792A2 (en) *	2001-04-12	2005-10-31	F. Hoffmann - La Roche Ag	DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US6949542B2 (en) *	2002-02-06	2005-09-27	Hoffman-La Roche Inc.	Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7531529B2 (en) *	2003-06-05	2009-05-12	Roche Palo Alto Llc	Imidazole derivatives
PL1651234T3 (pl) *	2003-07-25	2008-02-29	Hoffmann La Roche	Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
NZ551253A (en)	2004-06-01	2010-07-30	Hoffmann La Roche	Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
US7459563B2 (en)	2004-11-05	2008-12-02	Hoffmann-La Roche Inc.	Process for the preparation of isonicotinic acid derivatives
CA2620333A1 (fr)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
EP1942879A1 (fr)	2005-10-31	2008-07-16	Braincells, Inc.	Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
WO2007078819A2 (fr) *	2005-12-16	2007-07-12	Arkema Inc.	Procedes de fabrication d’un copolymere sequence a faible energie de surface et applications
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007134077A2 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenèse induite par le récepteur 5ht
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080188714A1 (en) *	2007-02-07	2008-08-07	Boston Scientific Scimed, Inc.	Electromechanical in-situ cleaning of optical elements
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ATE519751T1 (de)	2007-04-19	2011-08-15	Hoffmann La Roche	Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
TW200927731A (en) *	2007-09-14	2009-07-01	Ortho Mcneil Janssen Pharm	1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
NZ584152A (en)	2007-09-14	2011-11-25	Ortho Mcneil Janssen Pharm	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
HRP20110278T1 (hr)	2007-09-14	2011-05-31	Ortho-Mcneil-Janssen Pharmaceuticals	1',3'-disupstituirani-4-fenil,3,4,5,6-tetrahidro-2h,1'h[1,4']bipiridinil-2'-oni
ES2637794T3 (es)	2007-11-14	2017-10-17	Janssen Pharmaceuticals, Inc.	Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
US8193363B2 (en) *	2008-08-29	2012-06-05	Astrazeneca Ab	Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
MX2011003691A (es)	2008-10-16	2011-09-06	Ortho Mcneil Janssen Pharm	Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
CN102232074B (zh)	2008-11-28	2014-12-03	奥梅-杨森制药有限公司	作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (fr)	2009-05-12	2018-05-01	Janssen Pharmaceuticals, Inc.	Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
CN101891706B (zh) *	2010-04-09	2013-05-29	复旦大学	3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
US8642626B2 (en)	2010-07-29	2014-02-04	Taisho Pharmaceutical Co., Ltd.	Ethinyl-pyrazole derivative
WO2012020820A1 (fr)	2010-08-11	2012-02-16	大正製薬株式会社	Dérivé d'hétéroaryl pyrazole
CA2814996C (fr)	2010-11-08	2019-10-01	Janssen Pharmaceuticals, Inc.	Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
CA2815002C (fr)	2010-11-08	2019-10-22	Janssen Pharmaceuticals, Inc.	Derives 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
CN103261195B (zh)	2010-11-08	2015-09-02	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102276592B (zh) *	2011-06-17	2013-10-16	大连理工大学	一种奥氮平有关物质及其制备方法、分析方法
CA2847247C (fr)	2011-08-29	2019-10-15	Sanford-Burnham Medical Research Institute	Benzodiazepinones en tant que modulateurs de fonctions d'un recepteur metabotropique du glutamate, et utilisations neurologiques de ceux-ci
MX344308B (es) *	2011-11-03	2016-12-13	Merck Sharp & Dohme	Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
AR093077A1 (es)	2012-10-23	2015-05-20	Hoffmann La Roche	ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
CN102936223A (zh) *	2012-11-02	2013-02-20	江苏中丹药物研究有限公司	5-碘-2-甲基苯并咪唑的合成方法及纯化方法
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200036063A (ko)	2014-01-21	2020-04-06	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3096790B1 (fr)	2014-01-21	2019-07-10	Janssen Pharmaceutica, N.V.	Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
JP2017513844A (ja)	2014-04-23	2017-06-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
EP3154954B1 (fr)	2014-06-10	2022-02-09	Sanford-Burnham Medical Research Institute	Modulateurs allostériques négatifs (nam) du récepteur métabotropique du glutamate et utilisations de ceux-ci
CN108586447B (zh) *	2018-01-19	2021-01-29	中国人民解放军第四军医大学	一种苯二氮杂卓化合物及其制备方法和应用
CN108624674B (zh) *	2018-03-30	2020-11-24	青岛泱深生物医药有限公司	Krt73作为分子靶标在帕金森诊治中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU749836A1 (ru) *	1978-02-13	1980-07-23	Днепропетровский Ордена Трудового Красного Знамени Государственный Университет Им. 300-Летия Воссоединения Украины С Россией	Способ получени 4-метил2,3-дигидро1н-1,5-бензодиазепинонов-2
JPS6032775A (ja)	1983-07-30	1985-02-19	Daikin Ind Ltd	含フッ素ベンゾジアゼピン類
GB8601004D0 (en)	1986-01-16	1986-02-19	Fujisawa Pharmaceutical Co	1,5-benzodiazepine derivatives
GB9018601D0 (en)	1990-08-24	1990-10-10	Fujisawa Pharmaceutical Co	Tricyclic compounds
CA2054455A1 (fr)	1990-11-23	1992-05-24	John James Delany	Dihydro-2-oxo-1,5-benzodiazepines substituees en 2,3, et leur utilisation comme fongicides
DK0652871T3 (da)	1992-07-29	2001-12-03	Merck Sharp & Dohme	Absorberende artikel med fastgøringssystem, der tilvejebringer dynamisk tilpasning af elasticeret linning
GB9314981D0 (en)	1993-07-20	1993-09-01	Glaxo Spa	Chemical compounds
WO1996005818A1 (fr)	1994-08-19	1996-02-29	Nps Pharmaceuticals, Inc.	Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques
AU6514296A (en) *	1995-07-31	1997-02-26	Novo Nordisk A/S	Heterocyclic compounds, their preparation and use
KR100384979B1 (ko)	1995-09-07	2003-10-17	에프. 호프만-라 로슈 아게	심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
JP2001524468A (ja) *	1997-11-21	2001-12-04	エヌピーエスファーマシューティカルズインコーポレーテッド	中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
DK1224174T3 (da) *	1999-10-15	2004-01-26	Hoffmann La Roche	Benzodiazepinderivater
NZ518037A (en)	1999-10-15	2004-04-30	F	Benzodiazepine derivatives useful as metabotropic glutamate receptors
KR100566178B1 (ko) *	2001-04-12	2006-03-29	에프. 호프만-라 로슈 아게	ｍＧｌｕＲ2 길항물질 Ｉ로서의디하이드로-벤조[ｂ][1,4]디아제핀-2-온 유도체
HRP20030792A2 (en) *	2001-04-12	2005-10-31	F. Hoffmann - La Roche Ag	DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US6949542B2 (en) *	2002-02-06	2005-09-27	Hoffman-La Roche Inc.	Dihydro-benzo[b][1,4]diazepin-2-one derivatives

2000
- 2000-09-29 NZ NZ518037A patent/NZ518037A/en unknown
- 2000-09-29 HR HR20020260 patent/HRP20020260B1/xx not_active IP Right Cessation
- 2000-09-29 HU HU0203294A patent/HUP0203294A3/hu unknown
- 2000-09-29 CZ CZ20021663A patent/CZ20021663A3/cs unknown
- 2000-09-29 IL IL14910400A patent/IL149104A0/xx active IP Right Grant
- 2000-09-29 TR TR2002/01026T patent/TR200201026T2/xx unknown
- 2000-09-29 YU YU27902A patent/YU27902A/sh unknown
- 2000-09-29 PT PT00971302T patent/PT1224175E/pt unknown
- 2000-09-29 EP EP00971302A patent/EP1224175B1/fr not_active Expired - Lifetime
- 2000-09-29 AU AU10204/01A patent/AU779874B2/en not_active Ceased
- 2000-09-29 CA CA2386980A patent/CA2386980C/fr not_active Expired - Fee Related
- 2000-09-29 ES ES00971302T patent/ES2215738T3/es not_active Expired - Lifetime
- 2000-09-29 SI SI200030395T patent/SI1224175T1/xx unknown
- 2000-09-29 BR BR0014761-3A patent/BR0014761A/pt not_active Application Discontinuation
- 2000-09-29 DK DK00971302T patent/DK1224175T3/da active
- 2000-09-29 WO PCT/EP2000/009554 patent/WO2001029012A2/fr not_active Ceased
- 2000-09-29 RU RU2002110107/04A patent/RU2257382C2/ru not_active IP Right Cessation
- 2000-09-29 AT AT00971302T patent/ATE261945T1/de not_active IP Right Cessation
- 2000-09-29 KR KR10-2002-7004831A patent/KR100481386B1/ko not_active Expired - Fee Related
- 2000-09-29 MX MXPA02003740A patent/MXPA02003740A/es active IP Right Grant
- 2000-09-29 CN CNB008142211A patent/CN1199954C/zh not_active Expired - Fee Related
- 2000-09-29 DE DE60009116T patent/DE60009116T2/de not_active Expired - Lifetime
- 2000-09-29 JP JP2001531812A patent/JP3886805B2/ja not_active Expired - Fee Related
- 2000-09-29 PL PL00357433A patent/PL357433A1/xx not_active Application Discontinuation
- 2000-10-07 TW TW089121013A patent/TWI254044B/zh not_active IP Right Cessation
- 2000-10-11 CO CO00077374A patent/CO5251454A1/es not_active Application Discontinuation
- 2000-10-11 JO JO2000170A patent/JO2299B1/en active
- 2000-10-11 GC GCP2000949 patent/GC0000207A/en active
- 2000-10-12 PE PE2000001096A patent/PE20010759A1/es not_active Application Discontinuation
- 2000-10-13 US US09/687,241 patent/US6509328B1/en not_active Expired - Fee Related
- 2000-10-13 AR ARP000105385A patent/AR026028A1/es unknown
- 2000-10-13 MY MYPI20004818A patent/MY125506A/en unknown
2002
- 2002-04-04 ZA ZA200202654A patent/ZA200202654B/en unknown
- 2002-04-10 NO NO20021691A patent/NO20021691D0/no not_active Application Discontinuation
- 2002-04-11 IL IL149104A patent/IL149104A/en not_active IP Right Cessation
- 2002-04-15 MA MA26602A patent/MA26832A1/fr unknown
- 2002-11-20 US US10/300,449 patent/US6960578B2/en not_active Expired - Fee Related
2005
- 2005-06-07 US US11/146,693 patent/US7018998B2/en not_active Expired - Fee Related
2006
- 2006-02-27 US US11/363,351 patent/US7151098B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PE20010759A1 (es)	2001-07-19
JP3886805B2 (ja)	2007-02-28
JP2003512360A (ja)	2003-04-02
AR026028A1 (es)	2002-12-26
PT1224175E (pt)	2004-07-30
PL357433A1 (en)	2004-07-26
TR200201026T2 (tr)	2002-08-21
EP1224175A2 (fr)	2002-07-24
DE60009116D1 (de)	2004-04-22
US6509328B1 (en)	2003-01-21
KR100481386B1 (ko)	2005-04-08
MXPA02003740A (es)	2002-09-30
EP1224175B1 (fr)	2004-03-17
CZ20021663A3 (cs)	2002-09-11
HRP20020260B1 (en)	2004-12-31
SI1224175T1 (en)	2004-08-31
MY125506A (en)	2006-08-30
NZ518037A (en)	2004-04-30
US7151098B2 (en)	2006-12-19
CN1379764A (zh)	2002-11-13
DK1224175T3 (da)	2004-07-12
RU2257382C2 (ru)	2005-07-27
US7018998B2 (en)	2006-03-28
AU779874B2 (en)	2005-02-17
DE60009116T2 (de)	2005-02-17
ES2215738T3 (es)	2004-10-16
CA2386980A1 (fr)	2001-04-26
AU1020401A (en)	2001-04-30
HUP0203294A3 (en)	2003-03-28
BR0014761A (pt)	2002-07-02
IL149104A0 (en)	2002-11-10
HUP0203294A2 (hu)	2003-02-28
US20030092677A1 (en)	2003-05-15
IL149104A (en)	2006-12-10
YU27902A (sh)	2004-11-25
US20060148791A1 (en)	2006-07-06
GC0000207A (en)	2006-03-29
WO2001029012A2 (fr)	2001-04-26
HK1051037A1 (en)	2003-07-18
ATE261945T1 (de)	2004-04-15
CO5251454A1 (es)	2003-02-28
US6960578B2 (en)	2005-11-01
WO2001029012A3 (fr)	2001-11-08
TWI254044B (en)	2006-05-01
NO20021691L (no)	2002-04-10
CN1199954C (zh)	2005-05-04
ZA200202654B (en)	2003-09-23
KR20020047237A (ko)	2002-06-21
JO2299B1 (en)	2005-09-12
HRP20020260A2 (en)	2004-02-29
CA2386980C (fr)	2010-03-16
US20050234048A1 (en)	2005-10-20
NO20021691D0 (no)	2002-04-10

Publication	Publication Date	Title
MA26832A1 (fr)	2004-12-20	Derives de benzodiazepine.
MA26831A1 (fr)	2004-12-20	Derives de benzodiazepine."
TR200000520A3 (tr)	2001-06-21	4-Fenil-piridin türevleri.
DZ3159A1 (fr)	2001-04-19	Derives de purine.
MA26794A1 (fr)	2004-12-20	Derives de 5-phenyl-pyrimidine.
MA26504A1 (fr)	2004-12-20	Derives benzimidazole.
DZ3439A1 (fr)	2001-12-13	Derives de 2-aminocarbonyl-9h-purine
MA25499A1 (fr)	2002-07-01	Contacteur-disjoncteur.
MA26849A1 (fr)	2004-12-20	4-pyridinyle-n-acyl-l-phenylalanines.
PT1154988E (pt)	2004-12-31	Derivados de mevinolina
FR2810318B1 (fr)	2005-09-23	Derives de diamano-phenothiazine
MA26793A1 (fr)	2004-12-20	Derives de 4-phenyl-pyrimidine.
ITBO990359A0 (it)	1999-06-30	Elettromandrino .
DE60029755D1 (de)	2006-09-14	Congawandschutz.
DK1178990T3 (da)	2003-05-26	Imidazodiazepinderivat.
PT1088818E (pt)	2005-03-31	Derivados de quinolin-4-ilo
PT1194401E (pt)	2004-02-27	Derivados de diacil-hidrazina
NL1013652A1 (nl)	2000-05-25	Piperazinonderivaten.
ITBO990358A0 (it)	1999-06-30	Elettromandrino .
NO20015397D0 (no)	2001-11-05	1,5-Benzodiazepin-derivater
ES1044838Y (es)	2000-11-16	Friegasuelos.
ITSS990004V0 (it)	1999-06-08	Piramide - ricordo.
ES1044951Y (es)	2000-12-16	Tabique perfeccionado.
NO990502D0 (no)	1999-02-03	Pro.Karbo
ES1043620Y (es)	2001-02-16	Urna-columbario.